发明名称 Antibodies against phosphorylcholine in combination therapy with biologic agents
摘要 Antibodies against PC, PC conjugate or bioactive components and/or fragments thereof for use in combination therapy with one or more biologic agents and/or stem cells are disclosed, as well as compositions comprising the antibodies in combination with one or more biologic agents and/or stem cells. Also disclosed are PC conjugates, PC or bioactive components and/or parts/fragments thereof for use in activation immunotherapy prior to or in combination with treatment with biologic agents and/or stem cells for curing, treating, preventing, and/or reducing the risk of developing auto-immune diseases, chronic inflammatory diseases, and cancer diseases, as well as compositions comprising them in combination with biologic agents and/or stem cells.
申请公布号 US2016251426(A1) 申请公布日期 2016.09.01
申请号 US201615149969 申请日期 2016.05.09
申请人 Medirista Biotechnologies AB 发明人 FROSTEGÅRD Johan
分类号 C07K16/24;A61K35/28;C07K16/18;A61K39/395;C07K14/525;C07K16/28 主分类号 C07K16/24
代理机构 代理人
主权项 1. A method for curing, treating, preventing, and/or reducing the risk of developing autoimmune diseases, chronic inflammatory diseases, and cancer diseases, said method comprising administering PC or bioactive components and/or parts/fragments thereof as part of activation immunotherapy in combination with biologic agents and/or stem cells to a mammal, wherein said mammal is selected from the group comprising rabbits, dogs, cats, horses and humans; wherein said biologic agents are selected from the group comprising tumor necrosis factor alpha (TNFa) blockers, etanercept, infliximab, adalimumab, certolizumab pegol, golimumab, Interleukin 1 (IL-1) blockers, anakinra, monoclonal antibodies against B cells, rituximab, T cell costimulation blocker, abatacept, Interleukin 6 (IL-6) blockers, tocilizumab, or other antibodies, antibodies against oxidized phospholipids and/or oxidized lipoproteins and/or fragments or derivatives thereof, antibodies against apoB100 and/or fragments or derivatives thereof, anti-MDA-LDL, anti-OxLDL, anti-oxCL or anti-oxPS; and wherein said autoimmune diseases, and chronic inflammatory diseases, and cancer diseases are selected from the group comprising cardiovascular disease (CVD), atherosclerosis, atheromatous plaque rupture, myocardial infarction, acute coronary syndrome, stroke, transient ischemic attack (TIA), claudication, angina pectoris, diabetes mellitus type 1 and 2, Alzheimer's disease, dementia in general, rheumatic diseases, acute and/or chronic inflammatory conditions, rheumatoid arthritis, psoriasis, psoriatic arthritis, spondylopathies, ankylosing spondylitis, Reiter's Syndrome, systemic lupus erythematosus, dermatomyositis, Sjogren's syndrome, multiple sclerosis, myasthenia gravis, encephalitis, inflammatory bowel disease, arthritis, idiopathic inflammatory myopathies (IIM), dermatomyositis (DM), polymyositis (PM), inclusion body myositis, vasculitis (including Wegeners granulomatosus, Takayasu arteritis, temporal arteritis), polymyalgia rheumatica, bowel disease including Crohn's disease and colitis of different kinds, nephritis, or cancer diseases, non-Hodgkin's lymphoma, colorectal cancer, head and neck cancer and breast cancer.
地址 Stockholm SE